We're thrilled to be an official media partner for #EBMT26, and we can't wait to be on-site once again, filming our expert video interviews! 🎥🩸

Interested in joining us there or attending virtually?

Click here to register now:
➡️ buff.ly/bWxuru2

#BMTsm #HemOnc #ImmunoOnc @theebmt.bsky.social

Just one week to go until #CART26 kicks off in Palma de Mallorca, Spain, and online!🇪🇸 💻

Hear from the meeting chair, Annalisa Ruggeri, who encourages you to register for this hybrid meeting:
🎥 buff.ly/poXdp9x

Register here:
➡️ buff.ly/LMXQ0qU..

#CARTCell #ImmunoOnc #HemOnc @theebmt.bsky.social

🔍 We are looking for papers!

📩 Submit your latest research in the field of #CancerImmunology #ImmunoOnc

🖊️ Whether it is a Research Article, Short Report or Method, your paper would be suitable!

👉 Find out more details buff.ly/ZDb3rO0

EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC - VJOncology Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103...

Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.

🎥 Watch: buff.ly/kWn5KkI

#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate

At #IMS25, we spoke with Lisa Leypoldt, who shared findings from the cytogenetic subgroup analyses of the Phase II GMMG-CONCEPT trial evaluating Isa-KRd in newly diagnosed #myeloma.

Click here to watch:

🎥 buff.ly/Ut0Ne7p

#MMSM #MultipleMyeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky

Metastatic breast cancer updates at ESMO 2025 - VJOncology Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, provides an overview of the metastatic breast...

🎥Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, @HKUniversity, shares highlights from the #MetastaticBreastCancer track at #ESMO25 - including updates from VIKTORIA-1, novel ADCs in #TNBC, and PRO/QoL insights.

Watch here ➡️ buff.ly/E4FLjXD

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #ESMO25

🎥 Asya Varshavsky-Yanovsky shares insight into a study showing that a high peak in absolute lymphocyte count following cilta-cel infusion in patients with #myeloma predicts for increased risk of delayed neurological toxicities:

👉 buff.ly/MjL0Oku 👈

#CARTcell #MMSM #MultipleMyeloma #ImmunoOnc #IMS25

DESTINY-Breast05: T-DXd vs T-DM1 in high-risk HER2+ early breast cancer - VJOncology Charles Geyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, discusses results from the Phase III DESTINY-Breast05 trial (NCT04622319), comparing...

Charles Geyer, MD, reports #DESTINYBreast05 results in HER2+ early BC.

💊 T-DXd > T-DM1 for iDFS & DFS
🧠 Reduced brain mets risk
⚖️ Manageable safety → potential new SoC

🎥 buff.ly/r3AwOkw

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #Immunotherapy #HER2 #ESMO25 @myesmo.bsky.social

Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma.

Watch here:

👉 buff.ly/6GUNfkY 👈

#ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky

The IFNγ-CIITA-MHC II axis modulates melanoma cell susceptibility to NK-cell-mediated cytotoxicity

👉 buff.ly/tJzVEhb

#Melanoma #MELCSM #ImmunoOnc

The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉

We recently had the pleasure of speaking to Helen Parry to find out more about the study:

🎥 buff.ly/j1K0VV8

#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc

It was fantastic to catch up with @jmikhaelmd.bsky.social at #SOHO2025 to gain insight into areas of consensus & controversy in the current & future management of R/R #MultipleMyeloma!🩸

Watch the interview here:

👉 buff.ly/7AoA6tc 👈

#MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

EMERALD: eribulin plus dual HER2 blockade in first-line HER2+ breast cancer - VJOncology Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, comments on discusses final survival results from the EMERALD study (NCT03264547)...

Shigehira Saji, MD, PhD, shares final OS data from EMERALD in 1L HER2+ #BreastCancer.

💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk

#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25

#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product:

🎥 buff.ly/s2zXiCa

#ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

It was fantastic to catch up with the lovely Meral Beksac at #IMS25 to hear about strategies for improving CAR T-cell responsiveness and overcoming resistance in patients with #MultipleMyeloma.

Watch the interview here:

🎥 buff.ly/Rm44VmO

#MMsm #Myeloma #CARTCell #ImmunoOnc #BloodSky #HemeSky

DISCUS: comparing 3 vs 6 chemotherapy cycles before avelumab in aUC - VJOncology Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the Phase II DISCUS trial (NCT06892860), which evaluated whether...

At #ESMO25, Enrique Grande, MD, presents results from the Phase II DISCUS trial in aUC.

💊 3 vs 6 chemo cycles before avelumab maintenance
📈 Similar OS & PFS
💪 Better QoL & fewer toxicities with 3 cycles

🎥 buff.ly/UjqkfNT

@myesmo.bsky.social #BladderCancer #ImmunoOnc #GUcancer #Oncology

In an interview from #IMS25, Doris Hansen of @moffittnews.bsky.social outlined the results from a CIBMTR study assessing the safety and efficacy of cilta-cel in R/R #MultipleMyeloma.💉🩸

Watch here:

👉 buff.ly/fMxLmKd 👈

#IMS25 #MMsm #Myeloma #ImmunoOnc #CARTCell @myeloma-society.bsky.social

We recently caught up with Tycel Phillips of @cityofhope.bsky.social, who discussed progress being made in the development of predictive biomarkers of treatment response that can be used when administering bispecifics, CAR-T, or ADCs in #lymphoma:

🎥 buff.ly/Ho867Db

#LYMsm #ImmunoOnc #BloodSky

To learn about the role of the immune system as a mechanism of resistance to T-cell engagers in #MultipleMyeloma, make sure to watch our recent interview from #IMS25 with Samir Parekh. 🎥🩸

Click here:

👉 buff.ly/VceerXt 👈

#MMsm #Myeloma #HemOnc #ImmunoOnc #BloodSky #HemeSky #MedSky

The removal of the Risk Evaluation and Mitigation Strategy (REMS) program for CAR-T therapy is set to broaden access to CAR-T & cellular therapy outside of academic centers.💉🩸

Learn more about this in our recent interview with Muhammad Bilal Abid of @ttu.edu:

🎥 buff.ly/aPIlWiP

#HemOnc #ImmunoOnc

It was fantastic to catch up with Lorenzo Falchi of @mskcancercenter.bsky.social at #SOHO2025 to hear about the potential of bispecific antibody-based combinations for improving outcomes in patients with follicular #lymphoma.

Watch here: 👉 buff.ly/DDHwjBN

#LYMsm #ImmunoOnc #HemOnc #BloodSky

#iwAL25 | Charlie Craddock answers YOUR transplantation questions in a special Ask the Expert session!

Watch here:

👉 buff.ly/TRqoc4q%F0%9...

#HemOnc #ImmunoOnc #AMLsm #BMTsm #Leusm #BloodSky #HemeSky #MedSky

#IMS25 | Meera Mohan of @medicalcollegeofwi.bsky.social discusses a study investigating outcomes after a limited duration of bispecific antibody therapy in patients with R/R #MultipleMyeloma:

🎥 buff.ly/I3wa6uz

#MMsm #Myeloma #HemOnc #ImmunoOnc #BloodSky #HemeSky @myeloma-society.bsky.social

Thank you to Claudio Cerchione for stopping by at #IMS25 to share insight into the use of anti-CD38–based quadruplet regimens for patients with transplant-ineligible #MultipleMyeloma.🩸

Check out the interview here:

👉 buff.ly/jVocJUD 👈

#MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more - VJOncology Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of key studies in...

⭐ Jason Mouabbi, MD, of @mdanderson.bsky.social, shares an overview of key studies in breast cancer presented at #ASCO25:

🎥 buff.ly/0IeuM2Z

@ascocancer.bsky.social #BCSM #BreastCancer #CTSM #TrialUpdate #ImmunoOnc

KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer - VJOncology Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses the Phase III KEYNOTE-756 study (NCT03725059) of pembrolizumab with neoadjuvant chemotherapy...

⭐ Fabrice André, MD, PhD, shares KEYNOTE-756 results:

➡️ Adding pembrolizumab to neoadjuvant chemo improved pCR in high-risk ER+/HER2- breast cancer. EFS data pending...

🎥 buff.ly/0R25Yjb

#ESMOBreast25 #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc

At #SOHO2025, Sarah Tasian shared insights into the management of Ph-like ALL, highlighting the move toward an individualized, precision medicine approach.

Watch the interview here:

👉 buff.ly/E837gwk 👈

#ALLsm #Leusm #Leukemia #HemOnc #ImmunoOnc #BloodSky #HemeSky #MedSky

Thank you to the lovely Hang Quach of @unimelb.bsky.social for speaking with us at #IMS25 to share results from part one of the Phase I/II DREAMM-20 trial investigating belantamab in pts with R/R #MultipleMyeloma.🩸

Watch now:

🎥 buff.ly/zBD1MpN

#MMsm #Myeloma #CTSM #TrialUpdate #ImmunoOnc #HemOnc

It's always a pleasure to catch up with Hermann Einsele!😊

At #IMS25, Prof. Einsele outlined ongoing trials in #CARTCell therapy for #MultipleMyeloma.💉🩸

Click here to watch the interview:

👉 buff.ly/Bc1gG2R 👈

#CTSM #ImmunoOnc #MMsm #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

Want to hear about the safety & efficacy of the CD19-directed CAR-T var-cel (ARI-0001) in patients with CLL or Richter's transformation?💉🩸

Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:

🎥 buff.ly/AnTQebz

#CARTCell #ImmunoOnc #CLLsm #Leusm